MUDr. Libor Nechvatal s.r.o.
- Address
- lock Available on a paid plan
MUDr. Libor Nechvatal s.r.o. - Cardiovascular Research Center
MUDr. Libor Nechvatal s.r.o. is a specialized cardiovascular research facility dedicated to advancing treatment options for patients with complex cardiac conditions. The center demonstrates particular expertise in conducting Phase II and Phase III clinical trials focused on heart failure and atherosclerotic cardiovascular disease, with emphasis on innovative therapeutic approaches for patients with multiple comorbidities including kidney dysfunction and metabolic disorders.
- Heart failure with reduced, mildly reduced, and preserved ejection fraction (HFrEF, HFmrEF, HFpEF) including iron deficiency management and comorbid conditions
- Cardiovascular disease prevention and lipid management, including elevated lipoprotein(a) and atherosclerotic cardiovascular disease
- Novel therapeutic interventions combining heart failure treatments with metabolic therapies for patients with obesity
- Complex cardiovascular-renal interactions in heart failure patients with impaired kidney function
The research center's portfolio reflects a comprehensive approach to cardiovascular care, evaluating cutting-edge medications including combination therapies, siRNA therapeutics, and dual-action agents. With extensive experience in both dose-finding studies and large-scale outcomes trials, the facility contributes to the development of treatments addressing unmet needs in patients with chronic heart failure, atherosclerotic disease, and cardiovascular risk reduction, particularly in populations with elevated baseline risk or multiple comorbid conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Amgen Inc.2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG5trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MUDr. Libor Nechvatal s.r.o.
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.